Seattle AI consulting demand spans technology companies, aerospace, healthcare, and traditional industries. Technology Company AI Strategy: ML production readiness (consulting for technology companies that have AI experiments but need to move to production — assessing ML readiness across: data infrastructure (is the data pipeline reliable, scalable, and well-governed?), model development (are models reproducible, versioned, and tested?), deployment infrastructure (is there a reliable path from model to production?), monitoring (can the organization detect model drift and performance degradation?), and organizational readiness (do teams have clear ownership, processes, and incentives for ML production?) — for Seattle tech: many companies have individual data scientists building models in notebooks — the consulting engagement creates the organizational and technical framework for ML production), MLOps strategy (designing the ML operations strategy — model training pipelines (automated, reproducible training workflows), model registry (versioned model storage with metadata and lineage tracking), deployment automation (CI/CD for ML — automated testing, staging, and production deployment), monitoring and observability (tracking model performance, data quality, and infrastructure health in production), and retraining pipelines (automated model retraining triggered by performance degradation or new data availability) — for Seattle tech: MLOps strategy must account for the company's cloud platform (AWS SageMaker, Azure ML, GCP Vertex AI, or open-source stacks like MLflow + Kubeflow) and existing engineering practices), and AI product strategy (helping technology companies identify and prioritize AI-powered product features — which product capabilities would benefit from AI? What data is available to power these capabilities? What is the realistic timeline from concept to customer-facing feature? — for Seattle tech: AI product strategy prevents the common pattern of building AI features that are technically impressive but don't solve real customer problems — we help product teams validate AI feature concepts with customers before investing in development)). Aerospace AI Consulting: manufacturing quality AI (consulting for Boeing and aerospace suppliers on AI for manufacturing quality — computer vision for defect detection (identifying manufacturing defects in composite structures, machining, and assembly), predictive quality (predicting quality issues based on process parameters before defects occur), and digital twin integration (connecting AI quality models with digital twin representations of manufacturing processes) — for Seattle aerospace: manufacturing quality AI must meet AS9100 quality management standards and FAA production approval requirements — the consulting engagement defines an AI quality strategy that satisfies both technical requirements and regulatory constraints), supply chain AI (consulting for aerospace supply chain optimization — demand sensing (predicting aircraft delivery schedules and their impact on component demand), supplier risk assessment (monitoring supplier health indicators — financial stability, quality metrics, delivery performance — and predicting supplier disruptions), and inventory optimization (balancing the cost of aerospace parts inventory against the cost of production delays from parts shortages) — for Seattle aerospace: the aerospace supply chain is characterized by long lead times (some components require 12-18 months from order to delivery), strict quality requirements, and single-source supplier dependencies — AI consulting must account for these unique characteristics)). Healthcare AI Strategy: clinical AI roadmap (consulting for health systems on clinical AI adoption — identifying highest-value clinical AI use cases (which clinical decisions would benefit most from AI support?), assessing data readiness (is the clinical data warehouse sufficient for AI development? Are data quality and governance adequate?), evaluating regulatory pathway (does the AI application require FDA clearance/approval? If so, which regulatory pathway — 510(k), De Novo, PMA?), planning EHR integration (how will the AI capability be presented to clinicians within their existing workflow?), and designing validation studies (how will the AI's clinical accuracy and safety be demonstrated?) — for Seattle healthcare: clinical AI strategy must balance innovation ambition with the reality that clinical AI deployment takes 12-24 months from concept to bedside — including regulatory, validation, and integration timelines), and research AI strategy (consulting for research institutions on AI for research acceleration — literature mining (AI for systematic review and evidence synthesis), biomarker discovery (AI for identifying molecular signatures from multi-omics data), clinical trial optimization (AI for trial design, site selection, and recruitment prediction), and data collaboration (AI approaches that enable multi-institutional research without centralizing patient data — federated learning, synthetic data generation) — for Seattle research: AI strategy for institutions like Fred Hutchinson must account for IRB requirements, data sharing agreements, and the academic publication process)).